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IGF-1 Induces SREBP-1 Expression and Lipogenesis
in SEB-1 Sebocytes via Activation of the
Phosphoinositide 3-Kinase/Akt Pathway
Terry M. Smith1,2, Kathryn Gilliland1,3, Gary A. Clawson1,2 and Diane Thiboutot1,3
Understanding the factors that regulate sebum production is important in identifying therapeutic targets for
acne therapy. Insulin and IGF-1 stimulate sebaceous gland lipogenesis. IGF-1 increases expression of sterol
response element-binding protein-1 (SREBP-1), a transcription factor that regulates numerous genes involved in
lipid biosynthesis. SREBP-1 expression, in turn, stimulates lipogenesis in sebocytes. The goal of this study was to
identify the intracellular signaling pathway(s) that transduces the lipogenic signal initiated by IGF-1. Sebocytes
were treated with IGF-1 and assayed for activation of the phosphoinositide 3-kinase (PI3-K) pathway and of the
three major arms of the mitogen-activated protein kinase (MAPK) pathway (MAPK/extracellular signal-regulated
kinase (ERK), p38 MAPK, and stress-activated protein kinase/c-Jun-N terminal kinase). IGF-1 activated the MAPK/
ERK and PI-3K pathways. Using specific inhibitors of each pathway, we found that the increase in expression of
SREBP-1 induced by IGF-1 was blocked in the presence of the PI3-K inhibitor but not in the presence of the
MAPK/ERK inhibitor. Furthermore, inhibition of the PI3-K pathway also blocked the IGF-1-induced transcription
of SREBP target genes and sebocyte lipogenesis. These data indicate that IGF-1 transmits its lipogenic signal in
sebocytes through activation of Akt. Specific targeted interruption of this pathway in the sebaceous gland could
be a desirable approach to reducing sebum production and improving acne.
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INTRODUCTION
Sebum production is a critical factor in the pathogenesis of
acne, although the molecular signals involved in sebum
production are largely unknown. To design rational therapies
for acne, it is essential to understand the signaling pathways
that drive seborrhea in acne patients. Previous work has
shown that IGF-1 levels reach their peak in adolescents
during the growth spurt and then decline, which coincides
with the incidence of acne in many individuals (Deplewski
and Rosenfield, 1999). The same group has also shown that
IGF-1 stimulates sebaceous gland lipogenesis (Deplewski and
Rosenfield, 2000). Lipogenesis is also stimulated by IGF-1 in
sebaceous glands grown in organ culture (Downie et al.,
2002).
Recent reports indicate a correlation between severity of
acne in women and serum IGF-1 levels (Cappel et al., 2005).
Furthermore, studies show that IGF-1 increases lipogenesis in
the SEB-1 sebocyte model and this increase in lipogenesis is
accompanied by an increase in expression of sterol response
element-binding protein-1 (SREBP-1) mRNA and protein
(Smith et al., 2006). Dubbed, ‘‘master regulators of lipid
homeostasis’’, SREBPs have been shown to be regulated by
androgens in the hamster ear sebaceous model (Rosignoli
et al., 2003; Eberle et al., 2004). In other tissues and cell
lines, there have been numerous reports demonstrating
an increase in SREBP mRNA and protein in response to a
variety of stimuli (Kotzka et al., 1998; Foretz et al., 1999;
Chang et al., 2005). There is little doubt that an increase in
SREBP protein increases lipogenesis, particularly in the liver
(Goldstein et al., 2006). Here, we sought to extend these
findings to the sebaceous gland.
SREBPs bind sterol response elements, which are nucleo-
tide sequences found in the promoter regions of several
lipogenic genes in the cholesterol and fatty acid biosynthesis
pathways. There are three members in the SREBP family:
SREBP-1a, SREBP-1c, and SREBP-2. SREBP-1a and 1c are
transcribed by alternative start sequences, and the transcripts
are each spliced to form an identical protein from the second
exon onward. The longer first exon found in SREBP-1a makes
it the more potent activator of transcription, and more prone
to activate transcription of genes typically controlled by
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SREBP-2. There is functional overlap between SREBP-1 and
SREBP-2, but SREBP-1 typically controls genes in the fatty
acid biosynthesis pathway, whereas SREBP-2 controls trans-
cription of genes associated with cholesterol biosynthesis
(Shimano et al., 1997, 1999).
The goal of this study is to determine the molecular
signaling pathways by which IGF-1 stimulation of SEB-1
sebocytes increases SREBP-1 mRNA and protein. It has been
shown in other cell types that IGF-1 activates both the stress-
activated protein kinase/c-Jun-N terminal kinase (SAPK/JNK)
and the mitogen-activated protein kinase/extracellular signal-
regulated kinase (MAPK/ERK) cascades, in addition to the
phosphoinositide 3-kinase (PI3-K) pathway. Furthermore, all
three of these pathways have been implicated in activation of
SREBP in at least one model system. It is likely that the
molecular pathways governing the SREBPs may be tissue/cell
type specific. In this paper, we report that IGF-1 activates the
PI3-K and MAPK/ERK pathways in SEB-1 sebocytes, but not
the SAPK/JNK or MAPK/p38 pathways. Moreover, pharma-
cological antagonism of the MAPK/ERK pathway has no effect
upon the induction of SREBP-1 mRNA, protein, or lipogenesis
by IGF-1. Most importantly, induction of the PI3-K pathway
by IGF-1 mediates the increase in SREBP-1 mRNA, protein,
and lipogenesis in SEB-1 sebocytes. Finally, inhibition of the
PI3-K pathway with the inhibitor LY294002 completely
blocks the increase in lipogenesis in SEB-1 cells seen in
response to IGF-1. These data demonstrate that inhibition of
PI3-K signaling in the sebaceous gland decreases lipogenesis
and, as such, this approach may represent a novel strategy in
the treatment of acne.
RESULTS
The MEK inhibitor, PD98059, blocks the activation of MAPK/
ERK signaling by IGF-1, yet has no effect on the induction of
SREBP-1 by IGF-1
The MAPK/ERK pathway is activated when MAPK/ERK kinase
(MEK) phosphorylates p44 MAPK or p42 MAPK (ERK 1 and 2,
respectively). To determine if IGF-1 mediates its effect on
SREBP-1 expression in sebocytes through the MAPK/ERK
pathway, SEB-1 cells were treated with IGF-1 (20 ngml1) in
the presence and absence of the MEK inhibitor PD98059
(50 mM) and the effect on downstream mediators was
examined by Western blot. IGF-1 induced a robust increase
in phosphorylated p44/p42 protein in SEB-1 sebocytes after
24 hours (Figure 1a). Pretreatment of SEB-1 cells with 50 mM of
the MEK inhibitor PD98059 for 30minutes prior to the
addition of IGF-1 blocked activation of this pathway (Figure
1a), indicating that IGF-1 activates the MAPK/ERK pathway in
SEB-1 sebocytes. No cytotoxicity was observed with 50 mM
PD98059 treatment and cell counts at 24 hours showed no
difference from DMSO-treated cells (data not shown).
To determine if the MAPK/ERK pathway plays a role in the
induction of SREBP-1 by IGF-1, we treated SEB-1 cells with
PD98059 (50 mM) and/or IGF-1 (20 ngml1). Addition of the
MEK inhibitor failed to block the induction of SREBP-1 mRNA
(Figure 1b) or SREBP-1 protein (Figure 1c) by IGF-1,
indicating that IGF-1-induced expression of SREBP-1 is not
mediated by the MAPK/ERK pathway.
IGF-1 does not activate signaling through the p38 MAPK or the
SAPK/JNK pathways in SEB-1 sebocytes at 24 hours
In addition to signaling in cell growth and differentiation,
MAPKs are also involved in signaling pathways involving
inflammation and apoptosis. Both the p38 MAPK and the
SAPK/JNK are involved in these alternative pathways. To
determine if the p38 MAPK or the SAPK/JNK pathways
transduce the signal by IGF to increase lipogenesis, Western
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Figure 1. The MAPK/ERK pathway is activated by IGF-1 but does affect
SREBP-1 expression in SEB-1 cells. (a) Western blot reveals that p44/p42
(ERK1/2) is phosphorylated in SEB-1 cells treated with 20 ngml1 IGF-1 and
that this stimulation can be blocked by 50mM PD98059. The phospho-p44/
p42 blot was stripped and re-probed with an antibody that recognizes total
p44/p42 regardless of phosphorylation status to serve as a loading control.
These data indicate that IGF-1 activates the MAPK/ERK pathway and that this
activation is blocked in the presence of a MEK inhibitor. A representative of
five blots is shown. (b) SEB-1 cells were treated with MEK inhibitor PD98059
(50mM) and/or IGF-1 (20 ngml1) and QPCR was performed to quantify
SREBP-1a and -1c mRNA. Data are representative of six samples per
treatment group as analyzed by the REST-XL program. A P-value o0.05 was
considered statistically significant. Using the REST program, it is not possible
to generate SD or SE unless the same reverse transcription reaction is run
repeatedly, thus, P-values are used to gauge variation. These data indicate that
inhibition of the MAPK/ERK pathway does not abrogate the induction of
SREBP-1 mRNA by IGF-1. (c) Western blot was used to confirm that the MEK
inhibitor PD98059 did not block the induction of SREBP-1 protein by IGF-1 in
SEB-1 cells. Cells were treated as described in (b). After being probed for
SREBP-1, the membrane was stained with Simply Blue to ensure equal protein
loading. A representative of five blots is shown.
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blots were performed under the same experimental condi-
tions to determine the phosphorylation status of p38 MAPK
and SAPK/JNK in SEB-1 sebocytes stimulated with IGF-1. We
did not observe activation of either p38 or SAPK/JNK in
response to IGF-1, indicating that these pathways are not
critical for IGF-1-induced lipogenesis in sebocytes (Figure 2).
The PI3-K inhibitor, LY294002, blocks the increase in
transcription, translation, and processing of SREBP-1 that is
induced by IGF-1
Akt is a critical member of the PI3-K pathway. As such,
phosphorylation of Akt is a measure of activation of the PI3-K
pathway. To determine if the PI3-K pathway transduces the
signal by IGF to increase lipogenesis, Western blots for pAkt
and SREBP-1 were performed in the presence of the PI3-K
inhibitor, LY294002, with and without IGF-1. SEB-1 sebo-
cytes were found to have very low amounts of phosphory-
lated Akt when maintained in medium without serum.
However, the addition of IGF-1 (20 ngml1) to this same
medium induced a robust increase in phosphorylated Akt at
24 hours (Figure 3a). Importantly, we demonstrate that this
induction of phosphorylated Akt was blocked quite potently
by the addition of 50 mM of the PI3-K inhibitor, LY294002
(Figure 3a). No cytotoxicity was observed with 50 mM
LY294002 treatment. Minimal decreases in viable count
were observed after 24 hours of treatments as cells treated
with LY294002, both with or without IGF-1 stimulation had
approximately 10% fewer viable cells than the vehicle-
treated cells (data not shown).
We then treated SEB-1 cells with LY294002 and/or IGF-1
to determine if Akt activation was essential for the induction
of SREBP-1 mRNA and protein by IGF-1 that was observed in
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Figure 2. IGF-1 does not activate p38 MAPK or SAPK/JNK pathways in
SEB-1 cells. (a) A Western blot probing for phosphorylated MAPK/p38 reveals
that SEB-1 sebocytes do not phosphorylate p38 in response to IGF-1. C-6
glioma cells treated with anisomycin serve as a positive control for
phosphorylated p38, whereas unstimulated C-6 glioma cells represent the
negative control. The phospho-p38 blot was stripped and re-probed with an
antibody that recognizes total p38 as a loading control. This experiment was
repeated with no phosphorylation of p38 observed when the film was
overexposed. (b) A western blot probing for phosphorylated SAPK/JNK reveals
that SEB-1 sebocytes do not phosphorylate SAPK/JNK in response to IGF-1.
Total cell extracts from 293 cells treated with UV light (Cell Signaling
Technology) serve as a positive control for phosphorylated JNK, whereas
untreated 293 extracts serve as the negative control. The phospho-SAPK/JNK
was stripped and re-probed with an antibody that recognizes total SAPK/JNK
as a loading control. This experiment was repeated with no phosphorylation
of SAPK/JNK observed when the film was overexposed.
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Figure 3. IGF-1 activates the PI3-K/Akt pathway, which mediates the
increased expression of SREBP mRNA and protein in SEB-1 sebocytes.
(a) Western blot reveals that Akt is phosphorylated by IGF-1 at 24 hours and
that this induction is blocked when cells are treated with the PI3-K inhibitor
LY294002 for 30minutes prior to the addition of IGF-1. A representative of
five blots is shown. (b) SEB-1 cells were treated with 50 mM of the PI3-K
inhibitor LY294002 and/or 20 ngml1 IGF-1 for 24 hours and QPCR was
performed to quantify transcription of SREBP-1a and -1c. Data are
representative of six samples per treatment group as analyzed by the REST-XL
program. Using the REST program, it is not possible to generate SD or SE
unless the same reverse transcription reaction is run repeatedly, thus P-values
are used to gauge variation. These data indicate that inhibition of the PI3-K
pathway with LY294002 abrogates the IGF-1-induced increase in expression
of mRNA for both SREBP-1a and -1c. (c) A western blot probing for SREBP-1
was performed in SEB-1 cells in the presence or absence of PI3-K inhibitor
LY294002 and IGF-1 (20 ngml1). b-Actin was used as the loading control.
Data indicate that the precursor and mature forms of the SREBP-1 protein are
not induced by IGF-1 in the presence of the PI-3K inhibitor, which supports
the QPCR data above. A representative of five blots is shown.
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previous studies (Smith et al., 2006). We found that inhibition
of the PI3-K/Akt pathway by LY294002 blocked the induction
of SREBP-1 mRNA and protein by IGF-1 (Figure 3b and c).
IGF-1 induces lipogenesis in SEB-1 sebocytes via the PI3-K
pathway
As both the PI3-K and MAPK/ERK pathways are activated in
SEB-1 cells by IGF-1, we next wanted to dissect the
contribution of each of these signaling pathways to the
increase in lipogenesis noted in response to IGF-1 treatment.
We know that the MEK inhibitor PD98059 has no effect on
SREBP activation by IGF-1. Keeping in line with our central
hypothesis that SREBPs are important mediators of lipid
metabolism in SEB-1 cells, we hypothesized that treatment of
SEB-1 cells with an MAPK inhibitor would reduce lipogenesis
to a much lesser extent than treatment with a PI3-K inhibitor.
The 14C acetate incorporation assay was performed on SEB-1
cells treated with IGF-1 alone, or with the addition of
PD98059 or LY294002 in conjunction with IGF-1. IGF-1
increased lipogenesis as we have shown previously (Smith
et al., 2006). Additionally, treatment with MAPK inhibitor
PD98059 had no effect on this induction of lipogenesis
(Figure 4). However, when cells were treated with LY294002,
IGF-1 failed to induce lipogenesis, as cells in this treatment
group produce a lipid profile nearly identical to the group
that received no IGF. From this, we conclude that IGF-1
induces lipogenesis in SEB-1 cells via the PI3-K pathway
(Figure 4).
Numerically minor, yet statistically significant, decreases
in rates of lipogenesis were observed for nearly all lipids in
cells treated with either PD98059 or LY294002 in the
absence of IGF-1 relative to the DMSO-treated control. The
only exception were both the PD98059- and LY294002-
treated wax ester class, which were unchanged; and that the
cells treated with LY294002 actually had a statistically
significant increase in cholesterol oleate relative to the
unstimulated DMSO-treated control group. There were no
morphological changes to the cells. We would attribute these
minor changes in rate of lipogenesis to a slight decrease in
proliferation associated with inhibition of either the PI3-K or
MAPK pathway that is difficult to detect at 24 hours.
Analysis of transcriptional targets of SREBPs
We next sought to determine if the increase in nuclear SREBP
protein was accompanied by a corresponding increase in the
mRNA levels of SREBP transcriptional targets. Following
14 hours of IGF-1 treatment (20 ngml1), SEB-1 RNA was
isolated and QPCR was performed to determine the relative
amounts of fatty acid synthase, acyl-CoA synthetase, stearoyl-
CoA desaturase, squalene epoxidase, and HMG-CoA reduc-
tase. Transcription of each of these genes has been shown to
be activated by SREBP-1 in other models (Shimano et al.,
1997; Ikeda et al., 2001; Sakakura et al., 2001; Sone et al.,
2002; Chang et al., 2005; Murphy et al., 2006) and each
plays a role in lipogenesis. Here, we show that IGF-1
increases mRNA of each of these five genes, and further, this
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Figure 4. IGF-1 induces lipogenesis in SEB-1 sebocytes through activation of the PI3-K pathway. The 14C incorporation assay was performed on SEB-1
cells treated with 50mM of a pharmacological inhibitor of PI3-K (LY294002) or MAPK/ERK (PD98059) and/or IGF-1 (20 ngml1). IGF-1 induces a robust increase
in lipogenesis (horizontal striped bars vs solid black bars). Interestingly, addition of 50mM PD98059 to cells treated with IGF-1 has no effect on the IGF-1-
induced lipogenesis (diagonally striped bars vs white bars with black dots). Most importantly, the addition of 50mM PI3-K inhibitor LY294002 blocks any
induction of lipogenesis when cells are stimulated with IGF-1 (checkered bars vs black bars with white dots). All samples within an experiment were prepared in
triplicate, and each experiment was performed at least three separate times. Data were analyzed by Student’s t-test and considered significant if a P-value of
o0.05 was observed compared to the sample treated with the same inhibitor (DMSO-vehicle, LY294002, or PD98059) that did not receive IGF-1 treatment.
Additionally, treatment with PD or LY caused a statistically significant decrease in C, FOH, OA, SQ, and TAG relative to the unstimulated, untreated
control cells (diagonally striped or checkered vs horizontal stripe bars). C, cholesterol; CO, cholesterol oleate; FOH, fatty alcohols; OA, oleic acid; SQ,
squalene; TAG, triglycerides; WE, wax esters.
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effect was attenuated in the presence of the PI3-K inhibitor
LY294002 (Figure 5).
DISCUSSION
It is well established in the literature that expression of
SREBP-1 is increased in a variety of cell lines in response to a
litany of growth factors (Nadeau et al., 2004). Previous work
in the SEB-1 sebaceous cell model system has shown that
IGF-1 increases both expression of SREBP-1 protein and
lipogenesis (Smith et al., 2006). Recent reports indicate that
SREBP-1 and other lipogenic factors are also expressed in
sebaceous glands and the SZ95 sebocyte cell line (Harrison
et al., 2007). There are conflicting reports as to which
molecular pathway(s) is involved in transmitting the growth
factor signal that eventually leads to induction of the SREBPs
in other cell systems (Nadeau et al., 2004). In this study, we
sought to determine which pathway(s) is critical for the
induction of SREBP-1 protein by IGF-1 in SEB-1 sebocytes,
and furthermore, to determine which pathway(s) is important
for the increase in lipogenesis observed when SEB-1 cells are
stimulated with IGF-1. An understanding of the signaling
mechanisms that regulate the production of sebaceous lipids
can lead to the identification of potential therapeutic targets
to reduce sebum production and improve acne. To this end,
we studied the role of the PI3-K pathway and the three major
arms of the MAPK pathway (p38, SAPK/JNK, and p44/p42) in
mediating the lipogenic signal induced by IGF-1.
There are cell-type specific pathways that mediate signals
from growth factor receptors and that regulate the expression
of SREBP and lipogenesis (Nadeau et al., 2004). The p38
MAPK and the SAPK/JNK pathways are typically associated
with cell stress and are variably activated by growth factors.
In fact, activation of the IGF-1 receptor can actually
downregulate both pathways. Conversely, in the H292
pulmonary epithelial cancer cell line, keratinocyte growth
factor (KGF) activates the SAPK/JNK pathway to increase
SREBP protein and lipogenesis (Chang et al., 2005). Our data
indicate that neither the p38 MAPK nor the SAPK/JNK
pathways are activated in SEB-1 cells in response to IGF-1
stimulation, and thus would not be involved in the activation
of the SREBPs.
Numerous reports, particularly by groups using skeletal
myoctyes, have found the SREBPs to be activated by the p42/
p44 (ERK1/2) arm of the MAPK pathway in response to insulin
(Kotzka et al., 2000; Nadeau et al., 2004). When myocytes
were treated with insulin in the presence of PD98059, an
inhibitor of the p42/p44 MAPK pathway, the increase in
expression of SREBP-1 was blocked. However, in adipocytes,
the converse was true wherein the induction of SREBP-1 by
insulin was blocked in the presence of the PI3-K inhibitor,
LY294002, but not in the presence of the MAPK/ERK
inhibitor, PD98059. As expected, SEB-1 sebocytes stimulated
with IGF-1 display a robust activation of the p44/p42 MAPK/
ERK pathway (Figure 1) and also activation of the PI3-K
pathway (Figure 3). As activation of SREBP proteins has been
shown to increase transcription of several lipogenic genes
(Rawson, 2003), we hypothesized that one or both pathways
are responsible for the increase in SREBP and ultimately, the
increase in lipogenesis that we have observed previously with
IGF treatment (Smith et al., 2006).
As far as SREBP activation is concerned, we found that
inhibition of the p44/p42 MAPK pathway with PD98059 had
no effect on SREBP-1a or SREBP-1c mRNA, the translation of
SREBP-1 protein, or the processing of the protein into the
mature form in IGF-1 stimulated cells (Figure 1b and c). Here,
we establish that MAPK activation is not necessary for IGF-1-
induced activation of SREBPs in SEB-1 sebocytes. Impor-
tantly, inhibition of the PI3-K pathway with LY294002
blocked transcription of SREBP-1a and 1c mRNA, translation
of SREBP-1 protein, and also decreased the amount of the
mature SREBP-1 protein found in the nucleus of IGF-1
stimulated SEB-1 cells (Figure 3). This clearly implicates the
PI3-K/Akt pathway as the means by which IGF-1 mediates the
increase in SREBP-1 activity in SEB-1 sebocytes.
Recent reports indicate that activation of Akt is involved in
the transport of the SREBP cleavage activating protein/SREBP
complex from the endoplasmic reticulum to the Golgi (Du
et al., 2006). This is a major regulatory step in SREBP activity.
Our data indicate that IGF-1 increases the amount of cleaved
(mature) SREBP protein and that this increase in mature
protein can be blocked in the presence of the PI3-K inhibitor
(Figure 3c). This suggests that, in addition to possible
transcriptional/translational control, Akt activation may also
affect SREBP processing in SEB-1 sebocytes. Additional
experiments are needed to test this hypothesis.
Akt activation has been shown to increase the expression
of lipogenic genes (Porstmann et al., 2005). Microarray
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Figure 5. Inhibition of the PI3-K pathway in SEB-1 sebocytes abrogates the
induction of SREBP target genes by IGF-1. SEB-1 cells were treated with IGF-
1 (20 ngml1) in the presence or absence of 50 mm of the PI3-K inhibitor
LY294002, and QPCR was performed to ascertain the mRNA levels of several
transcriptional targets of SREBPs. IGF-1 induces a robust increase in the
expression of SREBP target genes that is blocked in the presence of the PI3-K
inhibitor (which blocks SREBP induction). Fatty acid synthase, acyl-CoA
synthetase, and stearoyl-CoA desaturase are traditional targets of SREBP-1, as
they are involved in fatty acid biosynthesis. Squalene epoxidase and HMG-
CoA reductase are involved in cholesterol biosynthesis. Data are
representative of five samples per treatment group as analyzed by the REST
program. Using the REST program, it is not possible to generate SD or SE
unless the same reverse transcription reaction is run repeatedly, thus P-values
are used to gauge variation. FAS, fatty acid synthase; ACS, acyl-CoA
synthetase; SCD, stearoyl-CoA desaturase; SQE, squalene epoxidase;
HMGCR, HMG-CoA reductase.
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analysis of gene expression was compared between retinal
pigment epithelial cells that express a constitutively activated
Akt construct and wild-type cells. Data indicated increased
expression of numerous genes involved in sterol and lipid
metabolism in the cells expressing activated Akt (Porstmann
et al., 2005). Additional experiments revealed that these gene
changes were mediated by an increase in the expression of
SREBP-1a and SREBP-1 c (Porstmann et al., 2005). These data
are supported by our observation that inhibition of Akt
activation blocks the increase in mRNA expression of
lipogenic genes induced by SREBP-1 (Figure 5).
After establishing that activation of the PI3-K pathway by
IGF-1 leads to an increase in mRNA for SREBP-1 and its target
genes, we sought to determine the role of the PI3-K pathway
in lipogenesis in SEB-1 sebocytes. Lipid production in
sebocytes is a key predictive end point for drugs that may
be of benefit in acne. Sebum, the lipid product of sebocytes,
consists primarily of cholesterol, triglycerides, and wax
esters. Here, we show that treatment with the PI3-K inhibitor
LY294002 blocks the robust induction of lipogenesis noted in
response to IGF-1 treatment for all lipids assayed. In contrast,
although IGF-1 activated the MAPK/ERK pathway in SEB-1,
inhibition of this pathway had no effect on the IGF-1-induced
lipogenesis in SEB1 cells (Figure 4). These data provide a
rationale for investigation of members of the PI3-K pathway
as drug targets to decrease sebum production and improve
acne. Topical application of an inhibitor to a specific
PI3-K isoform would be desirable, as the broad inhibition of
PI3-K by an oral agent renders it undesirable as a systemic
therapy.
The PI3-K enzyme consists of a p110 and a p85 subunit,
each of which has several isoforms. The p110a isoform is
activated in response to insulin and mediates the metabolic
effects of insulin, including glucose uptake (Knight et al.,
2006). Whether this isoform mediates the same effects in
sebocytes remains to be determined. Research is underway to
develop small molecule drugs to target several p110 iso-
forms. As it has been recently learned that p110a is frequently
mutated in human tumors, this class will come to the
forefront of cancer research (Samuels et al., 2004). Progress in
this area could be utilized to develop a topical inhibitor of
PI3-K to reduce sebum production. Although the pathogen-
esis of many diseases may be attributable to PI3-K signaling,
acne lends itself to the treatment with small molecules
inhibitors due to the accessibility of the sebaceous gland by
topical application, particularly lipophilic molecules.
Building on our previous work that showed that IGF-1
induces lipogenesis in SEB-1 sebocytes, here we have shown
that (1) the PI3-K molecular signaling pathway transduces the
IGF-1 signal, resulting in an increase in lipogenesis, (2) the
PI3-K pathway is essential for IGF-1 induced lipogenesis, and
(3) the increase in SREBP-1 nuclear protein is accompanied
by an increase in the transcription of several lipogenic genes
downstream of SREBP-1. As the p110a subunit of the PI3-K
molecule has recently been shown to mediate the insulin
signal, it is plausible that the small molecules designed to
inhibit this isoform of the protein could be useful in reducing
sebaceous gland lipogenesis and improving acne.
MATERIALS AND METHODS
Cell culture and treatments
SEB-1 (passage 22–27) SV40 immortalized human sebocytes were
grown to confluence in all experiments unless stated otherwise and
were cultured in standard medium consisting of DMEM with 5.5mM
glucose/Ham’s F-12 3:1, fetal bovine serum 2.5%, adenine
1.8 104 M, hydrocortisone 0.4 mgml1, insulin 10 ngml1, epi-
dermal growth factor 3 ngml1, and cholera toxin 1.2 1010 M
(Thiboutot et al., 2003).
For treatments with IGF-1, SEB-1 cells were plated at 7.6 105 in
a 100mm dish, or 1.3 105 in a 35mm dish and grown for 6 days.
On the sixth day, medium was removed; cells were washed twice
with phosphate-buffered saline, and given DMEM containing 5.5mM
glucose. IGF-1 was added 1:1,000 in 0.1 M acetic acid plus 0.1%
BSA for 24 hours. MEK inhibitor PD98059 (50 mM) was used as a
pharmacological inhibitor of the MAPK/ERK pathway, and cells were
pretreated with the compound 30minutes prior to stimulation with
20 ngml1 IGF-1. Likewise, the cell permeable PI3-K inhibitor,
LY294002, at a dose of 50 mM was also administered 30minutes prior
to IGF-1 treatment. Both compounds were suspended in DMSO and
the final concentration of DMSO in the media was 0.1%. Dose
response experiments (10, 20, and 50 mM) with each inhibitor were
conducted to determine the optimal concentration that inhibited
phosphorylation of Akt (LY294002) or ERK (PD98059). For each
inhibitor, optimal inhibition was obtained with the 50 mM concentra-
tion as has been commonly reported in other cell systems.
Lipogenesis assay
The incorporation of 14C-acetate into lipids was used as a measure of
lipogenesis as described previously (Smith et al., 2006). Briefly, SEB-
1 cells were grown to confluence in a 35mm dish and treated as
described above. Cells were trypsinized and resuspended in a
solution containing 1mCi 14C-acetate (New England Nuclear,
Boston, MA) in DMEM, and incubated for 2 hours at 371C with
agitation. Following the incubation, lipids were extracted twice with
ethyl ether and non-radioactive carrier lipids. The solvents were
evaporated under a stream of nitrogen gas, and lipids were taken up
in petroleum ether and separated by thin layer chromatography.
Lipid spots were visualized, excised, and radioactivity in each spot
was quantified in a liquid scintillation counter. All samples within an
experiment were prepared in triplicate, and each experiment was
performed at least three separate times. Data were analyzed by
ANOVA and considered significant if a P-value of o0.05 was
observed compared to the vehicle-treated control group.
Western blot
Protein was extracted using the Ne-Per kit (Pierce, Rockford, IL).
Both the precursor and mature SREBP-1 protein was found in the
nuclear lysate as described previously (Smith et al., 2006). This
appears to be unique to the SEB-1 cells, as the endoplasmic
reticulum is solubilized by the cytoplasmic detergents in the Ne-Per
kit. Western blot for the endoplasmic reticulum protein GRP-78
revealed that this marker was present in both the nuclear and
cytoplasmic fraction (data not shown). Thus, all blots shown using
SEB-1 extracts probed for SREBP-1 are the nuclear fractions. Twenty-
five micrograms of protein was run on a 4–12% Bis-Tris NuPage
polyacrylamide gel (Invitrogen, Carlsbad, CA). Protein was then
transferred to a polyvinylidene fluoride membrane and probed using
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standard methods. The SREBP-1 (K-10) antibody was purchased from
Santa Cruz (Santa Cruz, CA). In samples that were probed for
phospho-JNK, JNK, phospho-p38, p38, phospho-ERK, ERK, or
phospho-Akt, cytoplasmic protein lysates were used and the
antibody was purchased from Cell Signaling Technology (Boston,
MA). Membranes were probed with an anti-actin antibody or stained
with SimplyBlue (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions to ensure even protein loading.
C-6 glioma cells treated with anisomycin were used as a positive
control for phosphorylated p38, whereas unstimulated C-6 glioma
cells were the negative control. Total cell extracts from 293
cells treated with UV light served as a positive control for
phosphorylated JNK, whereas normal 293 extracts served as the
negative control. All control cell extracts were purchased from Cell
Signaling Technology.
Quantitative reverse transcription-PCR
For QPCR, cells were grown in standard medium for 6 days. On the
sixth day, cells were washed twice with phosphate-buffered saline
and pre-treated 30 minutes with the appropriate inhibitor/vehicles
prior to 14 hour treatment with 20 ngml1 IGF-1 in serum-free
DMEM. Total RNA was isolated and complementary DNA was
generated from 4.2 mg RNA/reaction primed with oligo-dT using the
SuperScript First-Strand Synthesis System for reverse transcription-
PCR (Invitrogen). QPCR was performed using the Brilliant SYBR
Green QPCR Core Reagent Kit in an Mx4000 Multiplex Quantitative
PCR System (Stratagene, La Jolla, CA). TATA-binding protein was
used as a reference gene. The following primer sequences were
used: TATA-binding protein upstream (GenBank number
NM_003194) 50-cacggcactgattttcagttct, TATA-binding protein down-
stream 50-ttcttgctgccagtctggact, SREBP-1a upstream (GenBank num-
ber NM_004176) 50-gctgctgaccgacatcgaa, SREBP-1c upstream
(GenBank number NM_001005291 50-ggagccatggattgcacttt, and
SREBP-1a, c downstream 50-tcaaataggccagggaagtca. Primer pairs
for fatty acid synthase (product number Hs00188012_m1), acyl-CoA
synthetase short-chain family member 2 (Hs002318766_m1),
stearoyl-CoA desaturase (delta-9-desaturase) (Hs00748952_s1),
squalene epoxidase (Hs00162288_m1), and HMG-CoA reductase
(Hs00168352_m1) were purchased from ABI (Foster City, CA). Data
were analyzed using the REST-XL& program (Pfaffl et al., 2002).
A P-value o0.05 was considered significant.
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